Navigation Links
Bacterial peptide provides new insight into common tumor suppressor
Date:7/7/2008

Scientists have identified a new antitumor drug that might prove useful in developing treatments for a multiple human cancers. The research, published by Cell Press in the July 8 issue of the journal Cancer Cell, advances the understanding of one of the most frequently disrupted tumor suppressor proteins in human cancer and provides new insight into the regulation of the complex process of cellular protein degradation under normal and pathological conditions.

"The cyclin kinase inhibitor p27kip1 is one of the most frequently dysregulated tumor suppressor proteins in human cancers and it correlates directly with patient prognosis," explains study author Dr. Nisar P. Malek from Hannover Medical School in Germany. "Due to increased turnover, p27kip1 is not sufficiently expressed in many human cancers. Therefore, targeting the p27kip1 degradation machinery might prove beneficial in the treatment of a variety of human malignancies."

Dr. Malek and colleagues had previously shown that stabilization of p27kip1 reduced progression of intestinal cancer. They sought to build on this earlier work by seeking to identify substances that reduce or block p27kip1 turnover and thereby allowing re-expression of the protein in tumor tissues. Using a cell screening assay, the researchers identified the peptide argyrin A, derived from the myxobacterium Archangium gephyra, as a stabilizer of p27kip1 and a potent, broadly acting antitumor drug.

Argyrin A induced apoptosis in cancer cells, prevented new tumor blood vessels from forming and targeted existing tumor blood vessels. Importantly, all antitumor activities of argyrin A depended on expression of p27kip1 and resistance to argyrin A was directly linked to loss of p27kip1. The researchers went on to reveal that the mechanism by which argyrin A reduces turnover of p27kip1 involves inhibition of the 20S proteasome, a complex that is involved in destruction of the majority of cellular proteins.

These findings show that argyrin A is a proteasome inhibitor that prevents turnover of p27kip1 and exerts potent antitumor activities. "The unique properties of argyrin A combined with its high activity at well-tolerated levels make this compound a good candidate for further clinical development," concludes Dr. Malek.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Reuse of Antibacterial Wipes Can Spread Bacteria
2. Scientist study bacterial communities inside us to better understand health and disease
3. Bacterial Infection May Boost SIDS Risk
4. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
5. Do bacterial combinations result in enhanced cytokine production? No!
6. Does Antibacterial Soap Work? At Least One Really Does.
7. Skin Friendly Releases Clinically Proven Hypoallergenic Anti-Bacterial Barrier Lotion
8. Bacterial battle for survival leads to new antibiotic
9. UCF technique promises to aid doctors ability to identify, treat bacterial infections
10. Why recovery from flu may increase odds of bacterial infection
11. Bacterial toxin closes gate on immune response, Penn researchers discover
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... ... , ... Apple Rehab Shelton Lakes , which specializes in the delivery ... as part of a disaster drill on October 3rd. , Apple Rehab participated with ... Manager, as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
Breaking Medicine Technology: